Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem

The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.

DRIVING THE INNOVATION ECOSYSTEM
M&A fuels innovation across a diverse and dynamic life sciences ecosystem.
LEVERAGING EFFICIENCY AND EXPERTISE
M&A drives efficiency and expertise across the life sciences industry, expediting the process of bringing new treatments and cures to market.
PRESERVING AMERICAN LEADERSHIP
M&A is a core component of the unique and world-class American life sciences ecosystem.

U.S. biopharmaceutical companies with establishments in every state

invested in R&D by top 15 biopharmaceutical companies

of biopharmaceutical companies operate without a profit

PARTNERS

ABOUT US

PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.

LATEST NEWS

M&A Powers Innovation to Fill Unmet Medical Needs

To address the unmet medical needs of those with rare diseases requires groundbreaking science in diseases that are not well understood, and this high degree of complexity often means that mergers and acquisitions (M&A) are critically important for companies to be successful in bringing new treatments to patients.

read more

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

Recent commentary from senior Federal Trade Commission (FTC) and Department of Justice (DOJ) officials signaled a continued commitment to an activist antitrust enforcement – compounding the uncertainty for thousands of small and early-state life science companies that depend on mergers and acquisitions (M&A) to bring new treatments to patients.

read more